gilead sciences
Jump to
39 Results Found
  • Gilead nears deal to buy Immunomedics for more than $20 billion: Report Sep 13, 2020 10:14 AM IST

    Gilead nears deal to buy Immunomedics for more than $20 billion: Report

    Discussions between Gilead Sciences and Immunomedics were initially centered around a partnership before shifting to a full-fledged takeover negotiation.

  • Pfizer signs deal to manufacture and supply Gilead's remdesivir for COVID-19 treatment Aug 07, 2020 06:07 PM IST

    Pfizer signs deal to manufacture and supply Gilead's remdesivir for COVID-19 treatment

    The US drugmaker would provide contract manufacturing services at its facility in Kansas to produce the drug.

  • Gilead's COVID-19 antiviral remdesivir gets conditional EU clearance Jul 03, 2020 07:20 PM IST

    Gilead's COVID-19 antiviral remdesivir gets conditional EU clearance

    The decision comes just days after the company allocated nearly all of its supply of the antiviral to the United States over the next three months, stirring concerns about availability elsewhere.

  • Coronavirus pandemic | Gilead Sciences will not launch remdesivir in India in July: Report Jul 03, 2020 01:09 PM IST

    Coronavirus pandemic | Gilead Sciences will not launch remdesivir in India in July: Report

    Hetero Labs and Cipla are the only Indian companies to have received the regulatory approval to market the experimental COVID-19 drug.

  • Coronavirus drug | Dr Reddy's inks pact with Gilead Sciences to manufacture remdesivir Jun 13, 2020 04:20 PM IST

    Coronavirus drug | Dr Reddy's inks pact with Gilead Sciences to manufacture remdesivir

    As per the non-exclusive licensing agreement, Gilead will grant Dr Reddy's Laboratories the right to register and manufacture its investigational Coronavirus drug remdesivir in 127 countries.

  • AstraZeneca contacted Gilead over potential megamerger: Report Jun 08, 2020 09:20 AM IST

    AstraZeneca contacted Gilead over potential megamerger: Report

    Such a deal would unite two of the drugmakers at the forefront of the industry's efforts to fight the new coronavirus and could be politically sensitive as governments seek control over potential vaccines or treatments.

  • COVID-19 treatment | Gilead says Indian licensees free to price Remdesivir: Report Jun 04, 2020 10:18 AM IST

    COVID-19 treatment | Gilead says Indian licensees free to price Remdesivir: Report

    Gilead Sciences' experimental drug Remdesivir has been found to aid in the recovery of COVID-19 patients.

  • US pharma giant seeks marketing authorisation from India for potential COVID-19 treatment drug May 30, 2020 12:37 AM IST

    US pharma giant seeks marketing authorisation from India for potential COVID-19 treatment drug

    Gilead Sciences, who is the patent holder of the drug, has the complete data about the pre-clinical and clinical studies for remdesivir, sources said.

  • Cipla: Respiratory pipeline adds oxygen, accumulate May 18, 2020 11:50 AM IST

    Cipla: Respiratory pipeline adds oxygen, accumulate

  • Health groups ask India to rescind Gilead's patents for COVID-19 drug remdesivir May 15, 2020 09:41 PM IST

    Health groups ask India to rescind Gilead's patents for COVID-19 drug remdesivir

    But health access groups say the pacts mean cheaper forms of the drug may not become available in nations seen as non-profitable to the five drugmakers.

  • Iran-linked hackers recently targeted coronavirus drugmaker Gilead May 09, 2020 05:25 PM IST

    Iran-linked hackers recently targeted coronavirus drugmaker Gilead

    In one case, a fake email login page designed to steal passwords was sent in April to a top Gilead executive involved in legal and corporate affairs, according to an archived version on a website used to scan for malicious web addresses.

  • Japan approves Gilead Sciences' remdesivir as COVID-19 drug May 07, 2020 09:55 PM IST

    Japan approves Gilead Sciences' remdesivir as COVID-19 drug

    Japan reached the decision just three days after the US drugmaker filed for fast-track approval for the treatment.

  • Exclusive: Gilead says open to collaborate with govts, drug firms to make Remdesivir globally available May 01, 2020 08:11 AM IST

    Exclusive: Gilead says open to collaborate with govts, drug firms to make Remdesivir globally available

    There is a possibility of Indian companies becoming part of the consortium, in the past Gilead used voluntary licenses to rope in Indian cos to manufacture and launch HIV and hepatitis-C medications in low-middle-income countries (LMICs).

  • US FDA moving with 'lightning speed' on Gilead's COVID-19 drug: Report Apr 30, 2020 08:15 PM IST

    US FDA moving with 'lightning speed' on Gilead's COVID-19 drug: Report

    "We're working with the company to emphasize the necessity of speed while at the same time to understand the data," FDA Commissioner Stephen Hahn said.

  • US stock index futures jump after Gilead's COVID-19 drug meets main goal Apr 29, 2020 06:55 PM IST

    US stock index futures jump after Gilead's COVID-19 drug meets main goal

    Data from the Commerce Department said gross domestic product fell at a 4.8 percent annualized rate in the January-to-March period, while economists in a Reuters poll were expecting a contraction of 4 percent.

  • Gilead puts emergency access to experimental coronavirus drug on hold amid surging demand Mar 23, 2020 11:30 AM IST

    Gilead puts emergency access to experimental coronavirus drug on hold amid surging demand

    Remdesivir has been touted by many - including President Donald Trump - as one of the more promising potential treatments for the virus.

  • Editor's Take | Drug companies in race to find vaccine and eliminate COVID-19 Feb 28, 2020 05:23 PM IST

    Editor's Take | Drug companies in race to find vaccine and eliminate COVID-19

    Moneycontrol's Shraddha Sharma talks to Prince Thomas to find out what drug companies are doing to find a cure for coronavirus.

  • Gilead warns against Hep C drugs from buyers clubs, says patients may be at risk May 22, 2017 01:36 PM IST

    Gilead warns against Hep C drugs from buyers clubs, says patients may be at risk

    Gilead warned that those (generic versions) medicines have not been approved for use in the countries into which they are imported.

  • Natco gets DCGI nod to launch hepatitis C drug in India Dec 15, 2015 12:43 PM IST

    Natco gets DCGI nod to launch hepatitis C drug in India

    “The company has received approval for the generic version of ledipasvir + sofosbuvir combination from Drugs Controller General (India)”, Natco Pharma said in a BSE filing today.

  • Gilead Sciences to set up manufacturing unit in Hyderabad Dec 07, 2015 09:28 AM IST

    Gilead Sciences to set up manufacturing unit in Hyderabad

    According to a press release issued by the Telangana government, Senior Director, South East Asia and Pacific, Aaron Brinkworth and Director, Government Affairs - Asia, Claudio Lilienfeld of Gilead Sciences met Chief Minister K Chandrasekhar Rao in camp office along with their team.

  • Battle coming for blockbuster cholesterol drugs Jul 25, 2015 04:02 PM IST

    Battle coming for blockbuster cholesterol drugs

    The injectable drugs, known as PCSK9 inhibitors, could cost an estimated USD 7,000 to USD 12,000 per year for each person using the drug.

  • Mylan launches Sovaldi tablets in India May 04, 2015 02:46 PM IST

    Mylan launches Sovaldi tablets in India

    In February this year, Gilead appointed Mylan as its exclusive distributor of Sovaldi in India. Mylan president Rajiv Malik said they have a history of partnering with Gilead to tackle key public health issues in India and around the world, beginning with expanding access to high quality and affordable HIV/AIDS antiretrovirals.

  • Cipla to launch generic Hepatitis C drug 'Hepcvir' in India Mar 25, 2015 04:17 PM IST

    Cipla to launch generic Hepatitis C drug 'Hepcvir' in India

    The availability of product in other markets is subject to approvals from the regulatory authorities in respective countries, Cipla said.

  • Dr Reddy's up 2% on pact with Hetero for Hepatitis drug Mar 24, 2015 03:23 PM IST

    Dr Reddy's up 2% on pact with Hetero for Hepatitis drug

    Shares of Dr Reddy's Laboratories gained 1.7 percent intraday Tuesday on agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences' Hepatitis C drug under the brand 'Resof' in India.

  • Zydus Cadila launches Gilead's Hepatitis C drug in India Mar 17, 2015 04:04 PM IST

    Zydus Cadila launches Gilead's Hepatitis C drug in India

    Zydus Cadila had recently signed a non-exclusive licensing agreement with Gilead Sciences to manufacture Sofosbuvir and the fixed dose combination of Ledipasvir/ Sofosbuvir for distribution in 91 developing countries including India.

Sections